School of Medicine
Showing 1-9 of 9 Results
-
Peter K. Jackson
Professor of Microbiology and Immunology (Baxter Labs) and of Pathology
Current Research and Scholarly InterestsCell cycle and cyclin control of DNA replication .
-
Siddhartha Jaiswal
Associate Professor of Pathology
Current Research and Scholarly InterestsWe identified a common disorder of aging called clonal hematopoiesis of indeterminate potential (CHIP). CHIP occurs due to certain somatic mutations in blood stem cells and represents a precursor state for blood cancer, but is also associated with increased risk of cardiovascular disease and death. We hope to understand more about the biology and clinical implications of CHIP using human and model system studies.
-
Iman Jaljuli
Postdoctoral Scholar, Pathology
BioPhD in Statistics,
Tel-Aviv University -
Olena Janczewski
Associate Director of Education, Pathology Ops Business Office
Current Role at StanfordAssociate Director of Education, Pathology
-
Kristin Jensen
Associate Professor of Pathology
Current Research and Scholarly InterestsI am a clinical translational investigator with a primary interest in breast cancer biology, and the use of investigational and clinical ancillary techniques such as gene and tissue microarray analysis and immunohistochemistry in the diagnosis and prognosis of this disease. As a practicing cytopathologist, I also have an interest in improving the fine needle aspiration biopsy diagnosis of breast lesions, again using immunohistochemistry and gene expression analysis as adjuncts to cytomorphology.
-
Rathinaraja Jeyaraj
Postdoctoral Scholar, Pathology
BioMy research interests revolve around unboxing, manipulating, and applying machine and deep learning algorithms to address computer vision challenges. Currently, I focus on histopathology image analytics using contrastive learning and multi-modal representation learning (image and text).
-
Jeyun Jo
Postdoctoral Scholar, Pathology
BioDr. Jeyun Jo received his Pharm.D. from Pusan National University in 2016 and his Ph.D. in pharmacy at the same institution in 2021. His thesis studies focused on the first total synthesis of anmindenol A and optimization of 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cells. He then worked for one year as a senior research scientist at Chong Kun Dang, a leading pharmaceutical company in Korea, where he developed large-sacale synthetic processes for engineered peptides. In May 2022, he joined the Bogyo lab at Stanford University as a postdoctoral fellow. His current research focuses on developing highly selective inhibitors and activity-based probes targeting specific serine hydrolases in pathogenic bacteria and cancer.
